Drugs / GL0034
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07385547 | Feb → Sep 2026 overdue | type 2 diabetes mellitus | Sun Pharmaceutical Industries, Inc. | Recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07282743 | Jan 2026 → Apr 2027 expected | type 2 diabetes mellitus | Sun Pharmaceutical Industries, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2025-11-12 | Sun Pharmaceutical Industries, Inc. | Results Sun Pharma Presents Two Posters on Utreglutide at ObesityWeek® 2025 sunpharma.com ↗
At Week 14, t he GL0034-treated participants achieved mean percent change of -6.8% in body weight, which sustained beyond initial treatment exposure through Week 17. |
| 2025-11-12 | Sun Pharmaceutical Industries, Inc. | Results Sun Pharma Presents Data from Phase 1b/2a Study of GL0034 at the American Heart Association 2025 Scientific Sessions sunpharma.com ↗ |
| 2024-06-22 | Sun Pharmaceutical Industries, Inc. | Results Sun Pharma’s GL0034 (Utreglutide) Demonstrates Significant Weight Loss, Gluco-metabolic and Lipid Lowering Efficacy in Individuals with Obesity in Oral Presentation at the American Diabetes Association 84th Scientific Sessions sunpharma.com ↗ |
| 2023-06-24 | Sun Pharmaceutical Industries, Inc. | Results ADA GL0034 Data Release sunpharma.com ↗ |
| 2020-06-24 | Sun Pharmaceutical Industries, Inc. | Results Sun Pharma Announces Pre-Clinical Data on GL0034 sunpharma.com ↗
The NCE demonstrated significant outcomes on various diabetic parameters evaluated, viz. glucose reduction, decrease in HbA1c (an important marker for clinical efficacy), augmented insulin secretion, lowering of glucagon level and a marked and meaningful reduction in triglyceride levels. |
All press releases naming this drug 5 releases
| Date | Issuer | Release |
|---|---|---|
| 2025-11-12 | Sun Pharmaceutical Industries, Inc. | Sun Pharma Presents Two Posters on Utreglutide at ObesityWeek® 2025 sunpharma.com ↗ |
| 2025-11-12 | Sun Pharmaceutical Industries, Inc. | Sun Pharma Presents Data from Phase 1b/2a Study of GL0034 at the American Heart Association 2025 Scientific Sessions sunpharma.com ↗ |
| 2024-06-22 | Sun Pharmaceutical Industries, Inc. | Sun Pharma’s GL0034 (Utreglutide) Demonstrates Significant Weight Loss, Gluco-metabolic and Lipid Lowering Efficacy in Individuals with Obesity in Oral Presentation at the American Diabetes Association 84th Scientific Sessions sunpharma.com ↗ |
| 2023-06-24 | Sun Pharmaceutical Industries, Inc. | ADA GL0034 Data Release sunpharma.com ↗ |
| 2020-06-24 | Sun Pharmaceutical Industries, Inc. | Sun Pharma Announces Pre-Clinical Data on GL0034 sunpharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GL0034 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07385547 ↗ |
| Route | Subcutaneous | “weekly subcutaneous administration” NCT07282743 ↗ |